Do Helicobacter pylori therapeutic vaccines need to be tailored to the age of the recipient?. (April 2012)

• Record Type: Journal Article
• Authors: Sutton, Philip; Robinson, Karen
• Is Part Of: Expert review of vaccines. Volume 11:Number 4(2012)
• Page Start: 415
• Page End: 417
• Publication Date: 2012-04
• Subjects: children -- Helicobacter pylori -- regulatory T cells -- Th17 -- therapeutic vaccine; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.12.16
• Languages: English
• ISSNs: 1476-0584

Abstract

Helicobacter pylori infections typically commence during childhood and last for life. Freire de Melo and colleagues compared cytokine profiles in the stomachs of H. pylori -infected and H. pylori -uninfected children and adults from Brazil. They suggest that the immune effector response in infected children differs from infected adults, specifically that stomachs of infected children contained elevated regulatory T-cell markers and less IL-17 compared with adults. As vaccine-mediated protection against H. pylori is believed to involve IL-17 and to be inhibited by regulatory T cells, this raises the possibility that individual H. pylori vaccines may have different efficacies in children and adults.